Xilio Therapeutics (NASDAQ:XLO) reported quarterly losses of $(0.72) per share. This is a 96.61 percent increase over losses of $(21.27) per share from the same period last year.
Pfizer And BioNTech Receive Positive CHMP Opinion For Omicron BA.1-Adapted Bivalent COVID-19 Vaccine Booster In European Union
CHMP recommendation based on safety, tolerability, and immunogenicity data from a Phase 2/3 trial of the Omicron BA.1-adapted bivalent vaccine
The Omicron BA.1-adapted bivalent COVID-19 vaccine combines
